RFA (Radiofrequency Ablation) for Liver Cancer: Which Cases Are Suitable? (2026 Update)

Radiofrequency ablation (RFA) is primarily used for liver cancers that are small in number and size and located away from major blood vessels and bile ducts. It is considered as an alternative to resection in very early- and early-stage liver cancer when surgical removal is not feasible.

Key Takeaways

• Radiofrequency ablation (RFA) is applied when the tumor is small, limited in number, and located away from major blood vessels and bile ducts.
• In very early- and early-stage liver cancer, it serves as an alternative to resection when the tumor's location or liver function makes surgical removal difficult.
• Even for tumors of the same size, eligibility for the procedure depends on the liver function grade (Child-Pugh) and portal pressure.
• Fever, abdominal pain, nausea, and fatigue are common for a day or two after the procedure, usually subsiding within a few days, with patients typically fit to return home within about ten days.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics, 2019–2023), which reflects nationwide statistics rather than any single institution's outcomes.

What Specific Types of Liver Cancer Is RFA Suitable For?

• The general indication for RFA is a small number of small tumors located away from major blood vessels and bile ducts.
• Liver cancer treatment decisions consider not just the stage but three factors together: first, the number, size, and vascular invasion of the tumor; second, liver function (the Child-Pugh grade, which combines bilirubin, albumin, coagulation values, ascites, and jaundice); and third, the patient's overall physical condition.
• In the very early and early stages—meaning small, few tumors with good liver function—liver resection is the first-line option. When the tumors are small and few but resection is difficult due to location or liver function, RFA is used to burn away the tumor instead.
• Microwave ablation is also considered under the same conditions as RFA—small, limited-number tumors located away from major vessels and bile ducts.

How Does RFA Differ from Embolization or Other Local Treatments?

• RFA uses a needle-type device to apply heat directly to the tumor site to destroy it, whereas transarterial chemoembolization (TACE) works by blocking the blood vessels that nourish the tumor, effectively starving it.
• RFA is mainly considered in very early- and early-stage disease with small, few tumors, while embolization is the core treatment for intermediate-stage disease with multiple tumors within the liver.
• Proton and carbon-ion (heavy-ion) therapy are described as alternatives for tumors that remain confined within the liver but are difficult to resect—particularly when they are close to major vessels or bile ducts, making both surgery and ablation risky. Whether this option applies depends on liver function and tumor location.
• Stereotactic body radiotherapy (SBRT) is described as an alternative for small tumors in locations unsuitable for ablation, or for use in combination with embolization.

What Does the Process Before and After RFA Look Like?

• Step 1 — Diagnosis and staging: Contrast-enhanced CT or MRI is used to confirm the characteristic blood flow pattern of liver cancer—strong enhancement in the arterial phase followed by washout—alongside tumor markers such as AFP.
• Step 2 — Liver function assessment: The Child-Pugh grade (combining bilirubin, albumin, coagulation values, ascites, and jaundice) and portal pressure are checked to determine whether the patient can tolerate the procedure.
• Step 3 — Indication review: Imaging is used to confirm the number, size, and location of tumors, specifically whether they are positioned away from major vessels and bile ducts.
• Step 4 — Procedure and recovery: Fever, abdominal pain, nausea, and fatigue are common for a day or two after the procedure, generally subsiding within a few days, with patients typically ready to return home within about ten days.
• Step 5 — Follow-up monitoring: During the first one to two years after treatment, contrast-enhanced CT or MRI and AFP testing are repeated every few months, with intervals gradually extended thereafter. Patients with chronic hepatitis B or C continue antiviral treatment and liver function testing for life.

FAQ — If My Liver Function Is Poor, Am I Ineligible for RFA?

For liver cancer, even with tumors of the same size and number, the available treatment options depend on liver function grade and portal pressure. When liver function is significantly impaired, ablation itself can be risky, and in such cases the focus may shift to symptom management, preserving liver function, and evaluating transplant eligibility. If you send your liver function test results along with imaging, the available options can be reviewed and explained to you.

FAQ — I've Had Multiple Rounds of Embolization. Can I Switch to RFA?

When response to repeated embolization declines, a shift toward systemic drug therapy or radiotherapy may be considered. The number and extent of previous procedures, along with imaging from each session, serve as key evidence for determining the next treatment step, so it is recommended that all such records be submitted.

Sources and Notes

• This article was written based on liver cancer reference materials (National Cancer Registration Statistics 2019–2023 from the National Cancer Center Korea's Central Cancer Registry, SEER 2016–2022, and explanations at the level of the National Cancer Information Center and NCCN patient guidelines).
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual conditions. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.